Home » Guidance Requires Diabetes Drug Trials to Gather Data on Heart Risk
Guidance Requires Diabetes Drug Trials to Gather Data on Heart Risk
January 16, 2009
Experimental Type 2 diabetes drugs approved for Phase II or III trials under an investigational new drug (IND) submission, including studies under way, are the subject of a final U.S. Food and Drug Administration (FDA) guidance on new methods of evaluating cardiovascular risk.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor